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Abstract This study assessed psychological distress
during the ﬁrst year after diagnosis in breast cancer patients
approached for genetic counseling at the start of adjuvant
radiotherapy and identiﬁed those vulnerable to long-term
high distress. Of the approached patients some chose to
receive a DNA test result (n = 58), some were approached
but did not fulﬁll criteria for referral (n = 118) and some
declined counseling and/or testing (n = 44). The compar-
ative group consisted of patients not eligible for genetic
counseling (n = 182) and was therefore not approached.
Patients actively approached for genetic counseling
showed no more long-term distress than patients not eli-
gible for such counseling. There were no differences
between the subgroups of approached patients. Predictors
for long-term high distress or an increase in distress over
time were pre-existing high distress and a low quality of
life, having children, and having no family members with
breast cancer. It is concluded that breast cancer patients can
be systematically screened and approached for genetic
counseling during adjuvant radiotherapy without imposing
extra psychological burden. Patients vulnerable to long-
term high distress already displayed high distress shortly
after diagnosis with no inﬂuence of their medical treatment
on their level of distress at long-term.
Keywords BRCA1/2 mutation searching  Genetic
counseling  Long-term psychological impact  Breast
cancer patients
Introduction
Breast cancer is among the most widely diagnosed cancers
in the world with an estimated 1.15 million cases world-
wide in 2002 [1]. The psychological effect of a breast
cancer diagnosis and subsequent treatment is well docu-
mented, revealing high distress in 20–30% of breast cancer
patients during the ﬁrst year after diagnosis. The majority
no longer experience serious psychological distress one
year after surgery [2–6]. Patient-related factors such as age,
personality characteristics, previous psychological treat-
ment, severely stressful non-cancer life experiences, pre-
existing general health complaints, illness perceptions and
postoperative distress are all related to long-term psycho-
logical distress. Objective cancer-related factors such as
TNM-stage and type of local or adjuvant treatment do not
inﬂuence psychological distress after diagnosis [3–7].
An estimated 5–10% of all breast cancers may be
accounted for by inherited autosomal dominant suscepti-
bility genes [8] accompanied by an increased risk for a
second breast and/or ovarian cancer [9]. Pre-symptomatic
DNA testing in families with a BRCA mutation is associated
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ally, no adverse psychological effects are observed
amongst carriers [10]. However, some characteristics of
applicants vulnerable to high distress have been identiﬁed
including: high pre-test distress, carrier status, complicated
grief, more affected ﬁrst-degree relatives, and strong
emotional illness representations [11, 12].
Among breast cancer patients diagnosed between
4 months and 32 years before undergoing genetic testing,
those diagnosed within the year prior to testing were more
anxious, reporting more breast-cancer-speciﬁc distress than
those with more than one year between diagnosis and
testing [13]. Affected mutation carriers, especially recently
diagnosed patients, showed a stronger decline in psycho-
logical well-being than unaffected mutation carriers two
weeks after the DNA result [14]. This potential negative
impact was also reported by Bonadona et al. [15].
A systematic active approach of recently diagnosed
breast cancer patients for BRCA1/2 mutation screening
increases patients’ awareness of genetic issues and may
positively inﬂuence the actual uptake for BRCA1/2 muta-
tion searching. Consequently, breast cancer patients are
included who might not have applied for genetic counseling
on their own initiative and who might show less psycho-
logical resilience than the previously studied non-affected
participants who applied on their own initiative [16]. The
future role of genetic counseling and BRCA testing during
the process of deciding on primary surgical treatment for
breast cancer [17–20] implies the time between diagnosis
and genetic counseling and testing will only become
shorter. Breast cancer patients will be approached for
genetic counseling during the most stressful period of
treatment, i.e. immediately after diagnosis.
Earlier we reported on the short-term psychological
responses of breast cancer patients to an active approach
for genetic counseling seven weeks after surgical treat-
ment, at the beginning of their adjuvant radiotherapy [21].
We found no increase in psychological distress shortly
after such an approach. Nor was there a difference in the
level or course of psychological distress between patients
approached for genetic counseling and those not eligible
and therefore not approached. However, of all approached
breast cancer patients, 50% showed high distress after ap-
proach. Approached patients vulnerable to short-term high
distress were younger, single, less optimistic, experienced
little social support, used an avoiding coping style and
displayed a lower quality of life and higher distress level
before approach for genetic counseling. To the best of our
knowledge no studies have reported on the long-term ef-
fects of such a pro-active approach in such an early stage of
treatment.
The aim of this study was to gain insight into the course
of psychological distress during the year following breast
cancer diagnosis in: (1) patients who receive a DNA-test
result, (2) patients who initially take part in genetic coun-
seling but who do not fulﬁll criteria for further counseling,
and (3) patients who decline genetic counseling and/or
testing. A second aim was to identify breast cancer patients
vulnerable to long-term high distress after being approached
for genetic counseling shortly after diagnosis.
According to a retrospective study among breast cancer
patients who received their carrier status some 2 months to
10 years after their cancer diagnosis, the majority believed
there was already an emotional overload in coping with the
diagnosis and treatment, and that offering DNA testing
shortly after learning they had cancer would have added
too much additional stress [22]. The majority of health
professionals were of the same opinion [22]. This report
gave us reason to expect a higher long-term psychological
distress among recently diagnosed breast cancer patients
approached for genetic counseling and BRCA testing
compared to patients not approached for counseling. We
expected the same factors to inﬂuence long-term levels of
distress as identiﬁed for short-term distress (see above)
[21]. Additionally, we expected highly distressed patients
to have more relatives with breast cancer [12, 23].
Patients and methods
Participants
Participants were breast cancer patients referred to the
University Medical Centre Utrecht for adjuvant radiother-
apy between January 2002 and March 2004. Inclusion
criteria were: a ﬁrst diagnosis of breast cancer, age between
18 and 75 years, and ﬂuent in the Dutch language.
Procedure
The procedure used in our initial approach for genetic
counseling has been described elsewhere [21]. Referred
breast cancer patients were recruited for our psychological
study prior to their ﬁrst visit to the Department of Radio-
therapy. During this ﬁrst visit they were assessed for
eligibility for genetic counseling using factors presumed
predictive for hereditary breast cancer [21]. If patients were
positive for at least one factor, they were actively ap-
proached to have a family pedigree drawn up ( = initial
approach). If this revealed at least one criterion for further
genetic counseling patients were referred to the Depart-
ment of Medical Genetics for further counseling and BRCA
1/2 mutation testing. The criteria were: (1) breast cancer in
patient or relative <40 years of age, (2) two or more rela-
tives with breast cancer, (3) multifocal, multicentric or
bilateral breast cancer in patient or relative with the ﬁrst
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123breast cancer diagnosed <50 years of age, (4) ovarian
cancer in patient or relative, and (5) a male relative with
breast cancer.
Patients completed questionnaires one week prior to
approach for genetic counseling (T0), four weeks after
initial approach (T1), three weeks after pedigree compila-
tion (T2), three weeks after the ﬁrst visit to the Department
of Medical Genetics (T3), and three weeks after receiving
DNA test results (T4) (Fig. 1). Questionnaires were
returned by mail. All participants completed T0 and T1.
Where the comparative group completed all ﬁve ques-
tionnaires, those approached for counseling only completed
three questionnaires in total. The timing of the third
questionnaire depended on when a patient left the genetic
counseling protocol, either due to ineligibility for further
counseling, after declining further counseling or after
receiving a DNA test result. This study was approved by
the Medical Ethics Committee of the University Medical
Centre Utrecht.
Measures
At baseline (T0) participants provided demographics (age,
marital status, number of children, educational level and
employment), information on family cases of breast cancer
and on their involvement with cancer in relatives. The
treating physician registered medical history including time
since surgery, type of surgery (mastectomy vs. lumpec-
tomy), extent of adjuvant therapy and TNM stage.
Participants completed the following psychological
characteristics:
Referral to Dept of 
Radiotherapy after 
Surgery n=669
T0  n=473 
6-7 weeks post surgery 
1 week prior to approach 
First visit radiotherapy 
7-8 weeks post surgery 
n=473
Checklist predictive factors 
If eligible initial approach 
for pedigree compilation 
No response 
n=196
T1
11-12 weeks post surgery 
4 weeks post approach 
Approached n=220 
T1
11-12 weeks post surgery 
4 weeks post approach 
Comparative n=182 
Pedigree compilation
15-16 weeks post surgery 
n=197
Accept referral 
for genetic counseling
n=65
T2
18 weeks post surgery 
11 weeks post approach 
No referral n=118 
T3
34 weeks post surgery 
27 weeks post approach 
Decline test n= 7 
T2
18 weeks post surgery 
11 weeks post approach 
Decline referral n= 14 
Decline pedigree
n= 23
T4
50 weeks post surgery 
43 weeks post approach 
DNA-test n=58 
   Total decline n= 44
Drop out 
n=71
Fig. 1 Study ﬂow scheme
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123– Utrecht Coping List (UCL) [24], a 15-item coping
strategy scale evaluating active coping, social support
seeking, avoidance and palliative reactions on a four-
point frequency scale from ‘almost never’ to ‘nearly
always’ (Cronbach’s alpha was 0.67–0.84 in a random
selection of Dutch cancer patients).
– The Optimism part of the Self-Assessment Question-
naire-Nijmegen (SAQ-N) [25, 26], an 8-item scale
measuring the level of optimistic outlook on life on a
four-point frequency scale ranging from ‘almost never’
to ‘nearly always’.
– The Quality of Life part of the EORTC-QLQ [27], a 2-
item subscale measuring general quality of life in cancer
patients on a seven-point Likert scale.
– A self-designed single item on social support, scoring
whether patients have someone to share personal prob-
lems and feelings with (‘no’, ‘yes, with one person’, and
‘yes, with more than one person’).
At each measurement (T0 through T4) participants
completed the following two outcome measures:
– Hospital Anxiety and Depression Scale (HADS) [28], a
14-item scale measuring anxiety and depression (7 items
each) with a total score ranging from 0 to 42. A total
score >13 is considered indicative of adjustment disorder
[29].
– Impact of Event Scale (IES) [30], a 15-item scale
measuring intrusion (7 items) and avoidance (8 items)
geared towards breast cancer as the distressing event. A
total score ‡26 is considered indicative of clinical
adaptation difﬁculties [31, 32].
To identify vulnerable patients, the total HADS and IES
scores at each measurement were dichotomized using the
cut-off scores for high psychological distress (HADS > 13,
IES ‡ 26). The development of both measures was identi-
ﬁed for each patient, yielding four patterns: (1) patients
scoring under the cut-off at baseline and at the last mea-
surement (low group), (2) patients scoring under the cut-off
at baseline and above the cut-off at the last measurement
(increasing group), (3) patients scoring above the cut-off at
baseline but drop below at the last measurement (decrease
group), and (4) patients scoring above the cut-off at baseline
and at the last measurement (high group). The high and
increase groups were considered vulnerable.
Statistical analysis
Using mixed models in the statistical program R (version
2.1.0.) accounting for the multiple measurement of each
individual patient and correcting for differences in medical
history, we analyzed courses of psychological distress and
whetherdistressdependsonapproachforgeneticcounseling
and/or participation in DNA testing. Based on dichotomized
baseline scores for psychological distress, the two low
baseline groups and the two high baseline groups were
compared on demographic characteristics, medical history
and psychological measures with non-parametric tests using
the Statistical Package for Social Sciences (SPSS 12.0).
Differences in univariate variables were analyzed using the
v
2-test on nominal variables and the Mann–Whitney test on
continuous variables. To identify predictors for long-term
high psychological distress, these variables were entered
into a binary logistic regression model using a forward, step-
wise, procedure model building strategy (Nagelkerke’s R
2).
Results
Characteristics of the study groups
Of the 669 breast cancer patients recruited for this
psychological study 473 (71%) returned the baseline
questionnaire. Of the 473, 402 (85%) patients completed at
least two measurements and were included in the study;
348 (74%) patients completed all measurements. Figure 1
shows participant details divided into four groups. Fifty-
eight patients received a DNA test result (DNA test group),
while the pedigree analyses showed 118 patients did not
meet criteria for further counseling (No referral group).
Patients who declined genetic counseling at any time were
grouped into the Decline group (n = 44). One hundred and
eighty-two patients were not eligible for genetic counseling
and were therefore not approached (Comparative group).
Differences between the total group approached and the
comparative group have been described elsewhere [21].
Table 1 gives the demographic characteristics and medical
history of the four groups.
Level and course of psychological distress
The four groups did not differ in level or course of
general anxiety and depression or breast-cancer-speciﬁc
distress. Nor did they differ in the percentage of patients
scoring above the cut-off scores for high anxiety and
depression or severe adaptation difﬁculties. Originally the
model was corrected for differences in medical history
between the four groups. However, no effect was iden-
tiﬁed proving a simpliﬁed model as sufﬁcient for the
investigation of the level and course of distress over
time. The course of psychological distress in all four
groups ﬁts a curvi-linear model, decreasing after the
initial approach up to week 27, followed by a small
increase up to week 43 (Figs. 2 and 3). The models that
best ﬁt the course of distress were:
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1239.3314 –0.1251 * time + 0.0027 * time
2 for anxiety
and depression (C.I. time –0.1745 to –0.0757,
p = 0.000 and C.I. time
2 0.0015–0.0038, p = 0.000)
and
25.6297 – 0.3457 * time + 0.0067 * time
2 for breast-
cancer-speciﬁc distress (C.I. time –0.4443 to –0.2471,
p = 0.000 and C.I. time
2 0.0044–0.0090, p = 0.000).
Predictors for pattern of psychological distress
Anxiety and depression (HADS)
Total baseline scores of anxiety and depression show a
Pearson correlation of 0.72 with total scores on the last
measurement. A pattern of anxiety and depression was
obtained for 215 of the 220 approached patients. The four
patterns did not differ on demographic characteristics or
medical history. Compared to the HADS low group, the
HADS increase group had a more avoiding coping style
(Z = –2.718, p = 0.006) and reported lower quality of
life (Z = –3.056, p = 0.002), more anxiety and depression
(Z = –4.231, p = 0.000) and more breast-cancer-speciﬁc
distress (Z = –2.777, p = 0.005) at baseline. The baseline
level of anxiety and depression was the only predictor for
an increase in anxiety and depression at the last measure-
ment (O.R. 1.416, C.I. 1.180–1.700, Table 2).
At baseline the HADS high group was less optimistic
(Z = –2.150, p = 0.031), experienced a lower quality of
life (Z = –3.272, p = 0.001) and reported more anxiety and
depression (Z = –2.710, p = 0.006) than the HADS
decrease group. A high pattern of anxiety and depression
was best predicted by lower perceived quality of life at
Table 1 Demographic and medical characteristics of breast cancer patients who received a DNA-test result, patients who were not eligible for
further counseling, patients who declined genetic counseling, and the comparative group
DNA-test (1)
(n = 58)
No referral (2)
(n = 118)
Decline (3)
(n = 44)
Comparative
(4) (n = 182)
v
2 p Sign.
differences
Demographics
Age, mean (range) 45 (24–70) 55 (41–74) 49 (28–72) 57 (40–74) 54.672 0.000
* 1–2, 1–4,
3–2, 3–4
With partner (%) 80.7 76.1 81.8 74.2 1.655 0.648
With children (%) 86.2 82.9 70.5 82.3 4.359 0.222
Education ‡ high school (%) 49.1 41.0 59.1 29.7 16.706 0.001
* 3–4
Employed at diagnosis (%) 73.7 58.1 59.1 44.5 16.920 0.001
* 1–4
Medical history
Days post operation, mean (range) 58.4 (21–201) 55 (19–153) 48 (13–141) 56 (9–182) 2.068 0.558
Mastectomy (%) 27.6 15.4 20.5 19.6 9.668 0.020
* 1–4
Adjuvant treatment
None (%) 46.6 57.3 45.5 70.3 16.779 0.001
* 4–1, 4–3
Chemo prior to RT (%) 13.8 6.8 18.2 4.4 11.487 0.007
* 4–3
Chemo after RT (%) 12.1 10.3 9.1 3.8 7.374 0.054
Hormone (%) 27.6 25.6 27.3 21.4 1.639 0.656
pN stage
0 43.1 56.9 53.5 65.3 9.564 0.022
* 1–4
1 50.0 40.5 44.2 33.5 5.779 0.123
2 5.2 0.9 2.3 – 8.254 0.009
* 1–4
3 1.7 1.7 – 1.1 0.942 0.921
Family history bc
None (%) 38.6 21.6 30.2 92.3 193.161 0.000
* 4–1, 4–2, 4–3
Only FDR bc (%) 21.1 22.4 27.9 1.1 52.643 0.000
* 4–1, 4–2, 4–3
Only SDR bc (%) 24.6 42.2 37.2 6.0 63.727 0.000
* 4–1, 4–2, 4–3
FDR + SDR (%) 15.8 13.8 4.7 0.5 29.947 0.000
* 4–1, 4–2
Involvement cancer in family (%) 33.9 37.6 25.0 28.5 3.727 0.291
* Signiﬁcant difference p < 0.05; RT = radiotherapy, FDR = ﬁrst degree relative, SDR = second degree relative, bc = breast cancer,
employed = employed outside the home upon diagnosis, pN stage = pathologic regional lymph node stage according to the UICC TNM
classiﬁcation of malignant tumors, ﬁfth edition
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123baseline (O.R. 0.912, C.I. 1.180–1.700) and having
children (O.R. 0.125, C.I. 0.018–0.863, Table 2).
Breast-cancer-speciﬁc distress (IES)
Total baseline scores and last scores on breast-cancer-spe-
ciﬁc distress showeda Pearson correlation of0.56.Apattern
for breast-cancer-speciﬁc distress was obtained for 214
approached patients. There were no differences between the
four patterns on demographics or medical history. Com-
pared to the IES low group, the IES increase group
demonstrated a more avoiding coping style (Z = –2.011,
p = 0.044)andahigheranxietyanddepression(Z = –2.063,
p = 0.038) and breast-cancer-speciﬁc distress (Z = –3.130,
p = 0.001) at baseline. An increase in breast-cancer-speciﬁc
distress was predicted by the level of breast-cancer-speciﬁc
distress at baseline (O.R. 1.181, C.I. 1.034–1.348, Table 2).
TheIEShighgroupreportedmoreanxietyanddepression
(Z = –3.400, p = 0.001) and breast-cancer-speciﬁc distress
(Z = –2.562, p = 0.010) at baseline than the IES decrease
group. In addition, the IES high group more often had no
breast cancer in the family (v
2 = 7.607, p = 0.009) and less
often only second-degree relatives with breast cancer
(v
2 = 9.836, p = 0.003). A high pattern of breast-cancer-
speciﬁc distress was predicted ﬁrstly by high anxiety and
depression at baseline (O.R. 1.222, C.I. 1.096–1.363),
followed by having no family members with breast cancer,
rather than only second-degree affected relatives (O.R.
2.680, C.I. 0.462–15.548) or both ﬁrst- and second-degree
relatives (O.R. 0.773, C.I. 0.167–3.588) (Table 2).
Discussion
Contrary to our expectations there was no adverse effect
from actively approaching recently diagnosed breast cancer
patients for genetic counseling or from their participation
in counseling and DNA testing during primary treatment.
Long-term psychological distress scales showed no
differences in either of our groups’ level or course of
psychological distress during the year following diagnosis.
The hesitance of health professionals to approach breast
cancer patients for genetic testing during primary treatment
[22] thus seems unwarranted, even though recently diag-
nosed patients experience more distress during genetic
counseling and testing than patients diagnosed earlier [13].
Perhaps the possibly hereditary nature of their cancer is not
as distressing as the diagnosis of breast cancer itself [33].
The possibility of a ceiling effect in distress after
diagnosis is not a valid explanation for the absence of
adverse effect since there was an increase in distress among
a subgroup of patients. This subgroup consisted mainly of
patients who reported higher levels of distress prior to
approach and included patients not referred for further
counseling, patients who declined counseling at some point
and some who received a DNA test result.
The curvi-linear course of psychological distress in all
groups may relate to primary treatment for breast cancer
combined with decreasing distress simply due to passing of
time [31]. Highest distress was noted close to diagnosis and
surgery, decreasing during adjuvant treatment and reaching
the lowest point at the end of radiation therapy. Anticipa-
tion of the annual mammogram and fear of a possible
recurrence or second breast cancer may account for the
small increase towards the end of the ﬁrst year after
diagnosis [34].
Considering earlier ﬁndings among breast cancer
patients, the present study supports psychological distress
at baseline as main predictor for later distress [5, 6] and the
absence of inﬂuence of breast cancer medical treatment
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Fig. 2 Fitted model for the course of the total HADS score measured
one week prior to approach and 4, 11, 27 and approximately 43 weeks
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week prior to approach and 4, 11, 27 and approximately 43 weeks
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123[3, 4, 6, 7], including approach for genetic counseling.
However, our study does not conﬁrm age, marital status
and level of optimism as relevant for long-term distress
[4, 7, 21].
Of the short-term psychological distress predictors [21],
only the reported quality of life prior to approach continued
to play a role in the prediction of long-term distress. We
identiﬁed new factors such as having children or having no
relatives with breast cancer. The role of having children in
long-term psychological distress is consistent with other
ﬁndings [20]. It is possible that during primary treatment
patients are overwhelmed by distress of their diagnosis and
thatonlyaftercompletingprimarytreatmentdotheybeginto
worry about the implications for their children thus making
this a more important and longer-term cause of distress.
The ﬁnding that patients with high baseline distress and
no relatives with breast cancer are more likely to remain
highly distressed does not conﬁrm ﬁndings by Van
Oostrom et al. [12] among healthy applicants from families
with known BRCA1/2 mutations. Besides negative expe-
riences of breast cancer in the family (e.g. extensive
treatment or loss of a family member), positive experiences
during course of treatment may occur yielding positive
effects on psychological distress. The subgroup of patients
with high baseline distress and no relatives with breast
cancer lack these experiences and therefore this potentially
positive effect.
In summary, our study suggests that breast cancer
patients can be approached for genetic counseling at the
beginning of adjuvant radiotherapy and undergo genetic
testing without adding an extra psychological burden. It
should be noted that our ﬁndings pertain solely to the af-
fected proband. We did not study effects of diagnosis and
consecutive genetic testing on family members. Nor did we
describe in the current write up the effects on the partners
of newly diagnosed patients. Additionally, although
patients were approached shortly after diagnosis, genetic
counseling and testing took approximately six months to
complete. Receiving a DNA result within three to six
weeks, as in true rapid testing, may affect the level and
course of patients’ distress differently. Another limitation
was the absence of a true experimental design since the
comparative group comprises patients ineligible for genetic
counseling and thus not approached.
Based on the present results, clinicians should preferably
have knowledge of patients’ psychological distress and
their perceived quality of life before approaching them for
genetic counseling in order to provide adequate support if
needed. Assessment should preferably take place using
standardized questionnaires, so results can be easily com-
pared to norms. Family history of breast cancer and whe-
ther a patient has children should also be noted.
Early detection of BRCA1/2 mutations is playing an
increasing role in decisions about surgical treatment
[16, 19]. Patients suspected of hereditary breast cancer who
have not reached a decision about deﬁnite local treatment
may beneﬁt from immediate genetic referral [17]. We have
shown that systematic screening with an active approach
Table 2 Signiﬁcant predictors
for long-term high
psychological distress: forward
stepwise binary logistic
regression model
QL = Quality of life,
FDR = ﬁrst degree relative,
SDR = second degree relative,
bc = breast cancer
v
2 PR
2 Increase R
2
N = 215
HADS low n = 134 (62.3%)
HADS increase n = 24 (11.2%)
Step 1 High HADS baseline 18.292 0.000 0.215
HADS decrease n = 24 (11.2%)
HADS high n = 33 (15.3%)
Step 1 Low QL baseline 11.891 0.001 0.291
Step 2 Having children 5.065 0.024 0.395 0.104
N = 214
IES low n = 87 (40.7%)
IES increase n = 12 (5.6%)
Step 1 High IES baseline 8.422 0.004 0.183
IES decrease n = 35 (16.4%)
IES high n = 80 (37.4%)
Step 1 High HADS baseline 18.745 0.000 0.242
Step 2 No family history bc 10.940 0.012 0.364 0.122
Only FDR 0.339
Only SDR 0.006
FDR + SDR 0.057
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123and participation in genetic testing during adjuvant radio-
therapy does not inﬂuence patients’ levels of distress long-
term. The next question is what the psychological impact
is of having genetic counseling and rapid BRCA results
before making surgical decisions.
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